Authors
Donel Martin, Ania Harvey, Bernhard Baune, Michael Berk, Gregory Carter, Vanessa Dong, Nick Glozier, Paul Glue, Sean Hood, Dusan Hadzi-Pavlovic, Maree Hackett, Natalie Mills, Shanthi Sarma, Andrew Somogyi, Anthony Rodgers, Colleen Loo
Publication date
2024/5/15
Journal
Biological Psychiatry
Volume
95
Issue
10
Pages
S201
Publisher
Elsevier
Description
Background
The cognitive profile of ketamine for treatment-resistant depression (TRD) remains uncertain, particularly with repeated doses, up-titrated for clinical response. Here we report results from the Ketamine for Adult Depression Study (KADS).
Methods
KADS was a randomized trial in 7 centres across Australia and New Zealand, comparing subcutaneous racemic ketamine to the active control midazolam (1: 1 ratio) twice weekly over 4 weeks. The study involved two cohorts; Cohort 1 (n= 68) tested a fixed dose regimen (0.5 mg/kg ketamine), while Cohort 2 (n= 106) involved response-titrated dosing (0.5-0.9 mg/kg). Cognitive measurements were assessed using the CogState battery at baseline and end of 4 weeks. Reliable Change Indices (RCI) scores were calculated for the randomised controlled phase.
Results
For both Cohorts there were no statistically significant differences between conditions for all 7 …
Scholar articles
D Martin, A Harvey, B Baune, M Berk, G Carter, V Dong… - Biological Psychiatry, 2024